Neurophet Secures FDA 510(k) Clearance for “Neurophet AQUA AD Plus,” Marking Its Third U.S. Regulatory Milestone

2026-02-06 - 16:48

Following AQUA and SCALE PET, the latest FDA clearance reinforces Neurophet’s leadership in AI-based Alzheimer’s disease imaging analysis Advanced analysis of neuroimaging features associated with cerebral microbleeds and edema supports imaging-based clinical decision-making and accelerates U.S. market expansion SEOUL, South Korea, Feb. 6, 2026 /PRNewswire/ — Neurophet (Co-CEOs Jake Junkil Been and Donghyeon Kim), an artificial